If they are both in use, the prescribing medical professional will determine the best timing for administration
How Retatrutide Compares to Existing Therapies The progression from single to dual to triple agonist therapy represents a clear trend in obesity pharmacotherapy: Semaglutide (GLP-1 agonist): ~1517% weight loss in Phase III (STEP trials) Tirzepatide (GIP + GLP-1 dual agonist): ~2022.5% weight loss in Phase III (SURMOUNT trials) Retatrutide (GIP + GLP-1 + glucagon triple agonist): ~2629% weight loss in Phase III (TRIUMPH-4) Each additional receptor pathway appears to contribute incremental efficacy
Antioxid Redox Signal 28:16261651 Diaz-Hung ML, Yglesias-Rivera A, Hernandez-Zimbron LF, Orozco-Suarez S, Ruiz-Fuentes JL, Diaz-Garcia A, Leon-Martinez R, Blanco-Lezcano L, Pavon-Fuentes N, Lorigados-Pedre L (2016) Transient glutathione depletion in the substantia nigra compacta is associated with neuroinflammation in rats
48 Together with the diversity of ubiquitin linkage types, this architectural variability gives the UPS its extraordinary precision, enabling tight regulation of proteostasis and preventing the accumulation of toxic proteins under physiological and pathological stress
Thats 10x or more what youd get through food
Months three through twelve This is where the Virta Health data becomes your benchmark